SMARTNCT07917247
Safety and Efficacy of Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Study sites: 0 to 1
- Study title shortened, about 1 word
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
the time to first adjudicated relapse from randomization
Timeframe: Baseline, Up To 48 Weeks or End of Study
Secondary (6)
Annualized relapse rate during any exposure to the experimental drugs
Relapse-free and steroid-free remission state at EOS visit
Change from baseline in dosage of prednisone at EOS visit
Change from baseline in EDSS score at EOS visit
Change from baseline in active MRI lesions at EOS visit
Show 1 moreShow less
Treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (TESAEs)
Arms and interventions
secukinumabExperimental
Secukinumab 300 mg s.c. (2 x 1 mL pre-filled syringe (PFS) 150 mg secukinumab) at Baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a protocol-specified prednisone taper regimen.
mycophenolate mofetilActive comparator
Mycophenolate mofetil (MMF) 1000 mg p.o. twice daily (Pediatric dose: 500-750 mg/m² body surface area, administered orally in two divided doses). MMF will be given in combination with a protocol-specified prednisone taper regimen.
Drugs: Secukinumab, Mycophenolate mofetil (MMF)
Sites
1 site in 1 country
- Chinese PLA General HospitalBeijing, China